Trial Profile
A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 29 Oct 2023
Price :
$35
*
At a glance
- Drugs Vodobatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sun Pharma Advanced Research Company
- 07 Sep 2023 This trial has been completed in Belgium, according to the European Clinical Trials Database record.
- 19 Jul 2023 Planned number of patients changed from 303 to 122.
- 19 Jul 2023 Planned primary completion date changed from 1 Jan 2026 to 1 Aug 2026.